| 朱晓鸥.糖肾化浊通脉颗粒对DKD患者NLRP3、IL-1、hs-CRP影响[J].浙江中西医结合杂志,2024,34(3): |
| 糖肾化浊通脉颗粒对DKD患者NLRP3、IL-1、hs-CRP影响 |
| Effect of Tangshen Huazhuo Tongmai Granule on NLRP3, IL-1, hs CRP in DKD Patients |
| 投稿时间：2023-06-07 修订日期：2023-12-18 |
| DOI： |
| 中文关键词: 糖尿病肾脏疾病 糖肾化浊通脉颗粒 NLRP3 IL-1 hs-CRP |
| 英文关键词:diabetes, kidney disease Tangshen Huazhuo Tongmai Granules NLRP3 IL-1 Hs CRP |
| 基金项目:CYP1B1-AS1/ROS轴介导大蒜素调控糖尿病肾病细胞焦亡的机制研究 省自然项目：2023J01121169 |
|
| 摘要点击次数: 360 |
| 全文下载次数: 0 |
| 中文摘要: |
| 目的 观察NLRP3、IL-1、hs-CRP与DKD的关系及探讨糖肾化浊通脉颗粒对DKD患者NLRP3、IL-1、hs-CRP的影响。方法 符合纳入标准的68例DKD患者，随机分为治疗组和对照组各34例。两组均予以西医基础治疗，治疗组在对照组治疗基础上加用糖肾化浊通脉颗粒，两组疗程均为12周。结果： 1.随着DKD分期升高NLRP3、IL-1、hs-CRP水平升高（P<0.05）。2.治疗组降低NLRP3、IL-1、hs-CRP、β2-MG、UAER优于对照组（P<0.05）。两组不良反应发生率未见明显差异（P＞0.05）。结论 糖肾化浊通脉颗粒可能是通过降低NLRP3、IL-1、hs-CRP水平从而改善T2DN炎症反应，延缓DKD进展。 |
| 英文摘要: |
| Objective: To observe the relationship between NLRP3, IL-1, hs CRP and DKD, and to explore the effect of Tangshen Huazhuo Tongmai Granule on NLRP3, IL-1, hs CRP in DKD patients. 68 DKD patients who met the inclusion criteria were randomly divided into a treatment group and a control group with 34 cases each. Both groups received basic Western medicine treatment, while the treatment group received Tangshen Huazhuo Tongmai Granules in addition to the control group. The treatment course for both groups was 12 weeks. Result: 1. As the DKD stage increased, the levels of NLRP3, IL-1, and hs CRP increased (P<0.05). 2. The treatment group reduced NLRP3, IL-1, hs CRP β 2-MG and UAER were superior to the control group (P<0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P>0.05). Conclusion: Tangshen Huazhuo Tongmai Granules may improve the inflammatory response of T2DN and delay the progression of DKD by reducing the levels of NLRP3, IL-1, and hs CRP. |
| 查看全文 查看/发表评论 下载PDF阅读器 |
| 关闭 |
